Halozyme Therapeutics | HALO - Umlaufvermögen

Aktienkurs
63.43
Täglich Wechseln
0.16 0.25%
Monatlich
-10.21%
Jährlich
-2.66%
Q1 Prognose
61.53




Umlaufvermögen Veränderung Datum
Acadia Pharmaceuticals USD 1.06B 14.31M 2025-12
Agios Pharmaceuticals USD 942.05M 91.06M 2025-12
Alnylam Pharmaceuticals USD 4.05B 97.85M 2025-12
Amarin USD 649.88M 21.55M 2025-12
Amgen USD 29.06B 1.17B 2025-12
Baxter International USD 6.87B 61M 2025-12
Cara Therapeutics USD 43.13M 4.18M 2025-06
Cytokinetics USD 916.97M 60.37M 2025-12
DBV Technologies USD 88.88M 32.36M 2025-09
Eli Lilly USD 55.63B 6.44B 2025-12
Esperion Therapeutics USD 462.57M 102.11M 2025-12
Halozyme Therapeutics USD 825.21M 503.54M 2025-12
Intrexon USD 23.72M 45.04M 2024-06
Ionis Pharmaceuticals USD 2.99B 471.01M 2025-12
MannKind USD 291.58M 67.26M 2025-12
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Nektar Therapeutics USD 281.36M 94.79M 2025-09
Pfizer USD 46.92B 3.22B 2025-09
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
United Therapeutics USD 3.7B 208.5M 2025-12
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12